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background:  There are limited data about transcatheter closure of ventricular septal defect (VSD). We present the largest single center 
cohort of transcatheter VSD closure in USA.
methods:  We reviewed 28 patients (pt) with transcatheter VSD closure performed between 1999-2013 (Table/Figure). Indications included 
post myocardial infarction VSD (PMIVSD) in 18 pt, iatrogenic VSD in 6 pt, and congenital VSD in 4 pt. We defined adverse event as death, 
device embolization, hemolysis requiring blood transfusion, and reintervention. Our primary endpoint was 30-day survival. Secondary 
endpoint was freedom from adverse event at 30 days and at last follow-up.
results:  Thirty-day survival was 89%, 100% and 100% in the PMIVSD, iatrogenic and congenital VSD cohort respectively. Adverse events 
occurred in 8 (44%) PMIVSD pt (death from multiorgan failure-2, device embolization-1, hemolysis-2, surgical VSD closure-2, deployment 
of a second VSD occluder-1), and one (17%) iatrogenic VSD pt (hemolysis); no complications occurred in congenital VSD pt. Cardiogenic 
shock (p=0.01) and VSD closure in acute PMI phase (p=0.006) were univariate predictors of adverse event in the PMIVSD cohort. No 
PMIVSD pt developed complication or required re-intervention beyond 30 days post procedure.
Conclusion:  Transcatheter VSD closure carries a moderate risk of peri-procedural complications in pt with PMIVSD but very low risk in 
congenital and iatrogenic pt. The risk of re-intervention at midterm follow-up was low in all groups. 
